Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent ...

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first direct-to-consumer commercial for the lung cancer med. | Ahead of the 10-year ...

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small cell lung cancer: Shanghai Wednesday, July 23, 2025, 14:30 Hrs ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...